The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized controlled phase II study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer.
Seiichi Nakamura
No relevant relationships to disclose
Shigeru Tatebe
No relevant relationships to disclose
Tetsu Shimizu
No relevant relationships to disclose
Nariyuki Yamane
No relevant relationships to disclose
Hideaki Nishidoi
No relevant relationships to disclose
Yasuro Kurisu
No relevant relationships to disclose
Hirotomo Kanayama
No relevant relationships to disclose
Haruaki Ogawa
No relevant relationships to disclose
Shunichi Tsujitani
No relevant relationships to disclose
Masahide Ikeguchi
No relevant relationships to disclose